TR201906773T4 - Amilin-mimetik bileşikleri ile polietilenglikolün aglomera olmayan biyokonjugatları. - Google Patents
Amilin-mimetik bileşikleri ile polietilenglikolün aglomera olmayan biyokonjugatları. Download PDFInfo
- Publication number
- TR201906773T4 TR201906773T4 TR2019/06773T TR201906773T TR201906773T4 TR 201906773 T4 TR201906773 T4 TR 201906773T4 TR 2019/06773 T TR2019/06773 T TR 2019/06773T TR 201906773 T TR201906773 T TR 201906773T TR 201906773 T4 TR201906773 T4 TR 201906773T4
- Authority
- TR
- Turkey
- Prior art keywords
- bioconjugates
- amylin
- agglomerated
- polyethylene glycol
- mimetic compounds
- Prior art date
Links
- 239000002202 Polyethylene glycol Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 title abstract 2
- 230000003941 amyloidogenesis Effects 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 210000000496 pancreas Anatomy 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
Abstract
Mevcut buluş genel olarak polietilen glikol ile amilin-mimetik bileşiklerinin yeni aglomera olmayan biyo-konjugatları ile ve bunların esas olarak pankreas gibi sistemik organların işlev bozukluğuna veya yetersizliğine katkıda bulunan, hücre dışı amiloid depolanması veya birikimi ile bağlantılı hastalıkların tedavisinde kullanımı ile ilgilidir.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRBR102013017626-5A BR102013017626A2 (pt) | 2013-06-14 | 2013-06-14 | Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças. |
Publications (1)
Publication Number | Publication Date |
---|---|
TR201906773T4 true TR201906773T4 (tr) | 2019-05-21 |
Family
ID=52021510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2019/06773T TR201906773T4 (tr) | 2013-06-14 | 2014-06-13 | Amilin-mimetik bileşikleri ile polietilenglikolün aglomera olmayan biyokonjugatları. |
Country Status (13)
Country | Link |
---|---|
US (2) | US20160331811A1 (tr) |
EP (1) | EP3007721B1 (tr) |
JP (1) | JP2016526533A (tr) |
CN (1) | CN105658234A (tr) |
AU (1) | AU2014280869B2 (tr) |
BR (1) | BR102013017626A2 (tr) |
CA (1) | CA2915104A1 (tr) |
ES (1) | ES2720274T3 (tr) |
MX (1) | MX368485B (tr) |
PL (1) | PL3007721T3 (tr) |
PT (1) | PT3007721T (tr) |
TR (1) | TR201906773T4 (tr) |
WO (1) | WO2014197961A1 (tr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR102015031283A2 (pt) * | 2015-12-14 | 2018-09-18 | Univ Rio De Janeiro | Bioconjugado de amilina humana ou de análogos de amilinanão agregantes, composição, métodos para a preparação deuma composição, para o tratamento de uma doença oucondição e para estabilizar um composto amilino-mimético, e,medicamento |
US10609584B2 (en) * | 2016-08-12 | 2020-03-31 | Telefonaktiebolaget Lm Ericsson (Publ) | Selection of a carrier in multi-carrier operation system |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6143718A (en) * | 1995-06-07 | 2000-11-07 | Amylin Pharmaceuticals, Inc. | Treatment of Type II diabetes mellutis with amylin agonists |
US7101853B2 (en) * | 1997-05-06 | 2006-09-05 | Amylin Pharmaceuticals, Inc. | Method for treating or preventing gastritis using amylin or amylin agonists |
AU2003235742B2 (en) * | 2002-01-08 | 2008-08-07 | Amylin Pharmaceuticals, Llc | Use of Amylin agonists to modulate triglycerides |
CA2501677A1 (en) * | 2002-10-22 | 2004-05-06 | Waratah Pharmaceuticals, Inc. | Treatment of diabetes |
US20050143303A1 (en) * | 2003-12-26 | 2005-06-30 | Nastech Pharmaceutical Company Inc. | Intranasal administration of glucose-regulating peptides |
US8114958B2 (en) * | 2004-02-11 | 2012-02-14 | Amylin Pharmaceuticals, Inc. | Amylin family peptides |
US7399744B2 (en) * | 2004-03-04 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Methods for affecting body composition |
US7879794B2 (en) * | 2005-03-31 | 2011-02-01 | Amylin Pharmaceuticals, Inc. | Methods for controlling binge eating disorders |
JP5137814B2 (ja) * | 2005-04-06 | 2013-02-06 | ジェンザイム・コーポレーション | 治療ターゲティングのための酸不安定リンカーを介するpegおよびポリシアルリソソーム酵素のコンジュゲート |
JP2008536881A (ja) * | 2005-04-21 | 2008-09-11 | ガストロテック・ファルマ・アクティーゼルスカブ | Glp−1分子と制吐剤との医薬製剤 |
EP1996617A2 (en) * | 2006-03-15 | 2008-12-03 | Novo Nordisk A/S | Amylin derivatives |
EP2102355B1 (en) * | 2006-12-14 | 2016-03-02 | Bolder Biotechnology, Inc. | Long acting proteins and peptides and methods of making and using the same |
EP2036923A1 (en) * | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
EP2036539A1 (en) * | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Stable formulations of amylin and its analogues |
JP2011520447A (ja) * | 2008-05-16 | 2011-07-21 | ネクター セラピューティックス | コリンエステラーゼ部分とポリマーとのコンジュゲート |
EP2300037B1 (en) * | 2008-06-17 | 2016-03-30 | Indiana University Research and Technology Corporation | Glucagon/glp-1 receptor co-agonists |
AU2009292643B2 (en) * | 2008-09-19 | 2016-02-18 | Nektar Therapeutics | Polymer conjugates of therapeutic peptides |
BRPI1003424A2 (pt) * | 2010-09-08 | 2013-01-08 | Univ Rio De Janeiro | sistema polimÉtrico de confinamento de amilina humana e anÁlogos agonistas, processo e uso; processo de avaliaÇço funcional de amilina liberada |
IL295201A (en) * | 2010-11-12 | 2022-10-01 | Nektar Therapeutics | Conjugations of a part of il-2 and a polymer, preparations containing them and their uses |
WO2012162547A2 (en) * | 2011-05-25 | 2012-11-29 | Amylin Pharmaceuticals, Inc. | Long duration dual hormone conjugates |
JP6040464B2 (ja) * | 2011-07-08 | 2016-12-07 | アエゲリオン・ファーマシューティカルズ・インコーポレイテッドAegerion Pharmaceuticals, Inc. | 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド |
US20140249076A1 (en) * | 2011-10-18 | 2014-09-04 | Astrazeneca Pharmaceuticals Lp | Amylin-calcitonin chimeric peptides conjugated to duration enhancing moieties |
US9830621B2 (en) * | 2013-03-14 | 2017-11-28 | Vdopia Inc. | Systems and methods for layering content |
-
2013
- 2013-06-14 BR BRBR102013017626-5A patent/BR102013017626A2/pt not_active Application Discontinuation
-
2014
- 2014-06-13 JP JP2016518806A patent/JP2016526533A/ja active Pending
- 2014-06-13 WO PCT/BR2014/000199 patent/WO2014197961A1/en active Application Filing
- 2014-06-13 CA CA2915104A patent/CA2915104A1/en not_active Abandoned
- 2014-06-13 US US14/898,237 patent/US20160331811A1/en not_active Abandoned
- 2014-06-13 AU AU2014280869A patent/AU2014280869B2/en not_active Ceased
- 2014-06-13 MX MX2015017356A patent/MX368485B/es active IP Right Grant
- 2014-06-13 PT PT14810520T patent/PT3007721T/pt unknown
- 2014-06-13 EP EP14810520.8A patent/EP3007721B1/en active Active
- 2014-06-13 CN CN201480033501.8A patent/CN105658234A/zh active Pending
- 2014-06-13 PL PL14810520T patent/PL3007721T3/pl unknown
- 2014-06-13 TR TR2019/06773T patent/TR201906773T4/tr unknown
- 2014-06-13 ES ES14810520T patent/ES2720274T3/es active Active
-
2015
- 2015-12-14 US US14/968,033 patent/US20160184401A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20160331811A1 (en) | 2016-11-17 |
PT3007721T (pt) | 2019-05-13 |
CN105658234A (zh) | 2016-06-08 |
JP2016526533A (ja) | 2016-09-05 |
EP3007721B1 (en) | 2019-02-27 |
BR102013017626A2 (pt) | 2015-02-10 |
PL3007721T3 (pl) | 2019-09-30 |
AU2014280869A1 (en) | 2016-01-07 |
WO2014197961A1 (en) | 2014-12-18 |
US20160184401A1 (en) | 2016-06-30 |
ES2720274T3 (es) | 2019-07-19 |
EP3007721A1 (en) | 2016-04-20 |
MX368485B (es) | 2019-10-04 |
EP3007721A4 (en) | 2016-12-07 |
CA2915104A1 (en) | 2014-12-18 |
AU2014280869B2 (en) | 2017-11-02 |
MX2015017356A (es) | 2016-12-20 |
WO2014197961A9 (en) | 2016-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201892386A1 (ru) | Химерные нейротоксины | |
GT201700033A (es) | Anticuerpos anti tigit | |
ECSP17021754A (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
CL2015002472A1 (es) | Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4. | |
WO2016106403A3 (en) | Therapeutic compositions and methods for malignant tumors with rnai molecules targeted to hsp47 and p21 | |
EA201790378A1 (ru) | Заключенное в липосому аффинное лекарственное средство | |
MX2015017532A (es) | Métodos para modular la actividad del regulador de transmembrana de fibrosis quística. | |
UA118558C2 (uk) | Пептидна сполука | |
WO2014145159A3 (en) | Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use | |
EA201391392A1 (ru) | Синтетические наноносители с осмотически опосредованным высвобождением | |
EA201692526A1 (ru) | Замещенные [1,2,4]триазольные соединения | |
MX2022014277A (es) | Metodos para una mejor administracion de agentes activos a tumores. | |
BR112015029386A2 (pt) | uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer | |
CL2016002091A1 (es) | Compuesto de triazina y su uso para fines medicinales | |
CL2015002897A1 (es) | Inhibidores de bace1 | |
EA201890747A1 (ru) | Способы лечения воспалительных заболеваний | |
CL2015001202A1 (es) | Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer. | |
UY34616A (es) | Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias. | |
UY35747A (es) | Derivados sustituidos de fenilalanina | |
CY1122403T1 (el) | Μορφες δοσολογιας και θεραπευτικες χρησεις της l-4-χλωροκυνουρενινης | |
EA201890212A1 (ru) | Новое применение сульфата декстрана | |
CL2016002839A1 (es) | Derivados de carboxamida | |
EA201590503A1 (ru) | Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями | |
DOP2015000176A (es) | Compuestos de azetidiniloxifenilpirrolidina | |
UY35745A (es) | Derivados sustituidos de fenilalanina |